Last reviewed · How we verify

Repatha biosimilars

Complete Repatha (EVOLOCUMAB) biosimilar landscape: 5 approved biosimilars, 0 filed, 4 in Phase 3. Sponsor, approval status, first approval date, and patent timeline for the originator.

5 approved 0 filed 4 Phase 3 All key patents expired

About Repatha

Repatha (EVOLOCUMAB) — originally marketed by Repatha. Class: PCSK9 Inhibitor [EPC]. Target: PCSK9. Area: Metabolic. First approved 2015-01-01.

Approved biosimilars (5)

BiosimilarSponsorPhaseFirst approvalCountry
Evolocumab Auto-Injector [Repatha] Imperial College Healthcare NHS Trust marketed
Evolocumab Cartridge NYU Langone Health marketed
Evolocumab combined with statins Zibo Central Hospital marketed
Evolocumab Prefilled Syringe University of Erlangen-Nürnberg Medical School marketed
Evolocumab or Alirocumab Rigshospitalet, Denmark marketed

Filed biosimilars under regulatory review (0)

No biosimilars currently under regulatory review.

Phase 3 biosimilars (4)

BiosimilarSponsorPhaseFirst approvalCountry
Evolocumab AMD Amgen phase 3
evolocumab and LDL apheresis Hospital General Universitario Gregorio Marañon phase 3
Evolocumab Pre-filled Syringe Amgen phase 3
Evolocumab AI/pen Amgen phase 3

Originator patent timeline

Active patents (0)

No active patents tracked.

Expired patents (0)

No expired patents tracked.

Subscribe to biosimilar updates

Every regulatory action on Repatha or any of its biosimilars:

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing